Skip to content
2000
Volume 25, Issue 3
  • ISSN: 1871-5303
  • E-ISSN: 2212-3873

Abstract

Objective

Primary Hyperparathyroidism (PHPT) is a common disease, frequently diagnosed in post-menopausal women, among whom Osteoporosis (OP) is a common finding. To date, no study has specifically evaluated the asymptomatic PHPT (aPHPT) patients without OP, in particular post-menopausal women who are exposed to an increased risk of developing OP.

Materials and Methods

This study involved a retrospective cross-sectional evaluation. From our database of 500 consecutive patients diagnosed with PHPT, 178 post-menopausal aPHPT were retrieved.

Results

The clinical, biochemical, and imaging data of the 85 patients without OP were not different from those of the 93 with OP, except for bone alkaline phosphatase (significantly higher in the latter group). Among these 85 patients without OP, the 45 patients meeting surgical criteria for parathyroidectomy had significantly higher values of serum PTH (240 . 99 ng/L, =0.03) and calcium (total, 11.2 ± 0.7 . 10.6 ± 0.4 mg/dL, <0.001; ionized, 1.45 ± 0.12 . 1.36 ± 0.8 mmol/L, =0.044) and lower values of serum phosphate (2.57 ± 0.7 . 2.94 ± 0.5 mg/dL, =0.009) and eGFR (68.5 ± 23.8 80.8 ± 14.4 mL/min/1.73 m2, =0.006) than the 40 aPHPT patients not meeting surgical criteria, without any difference in densitometric data and calculated fracture risk.

Conclusion

In our series, post-menopausal aPHPT patients without OP accounted for almost a sixth of the whole PHPT series. About half of these patients did not meet surgical criteria, but their T scores and 10-year fracture risk calculated by FRAX were not significantly different from post-menopausal aPHPT without OP meeting surgical criteria.

© 2025 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/emiddt/10.2174/0118715303288678240424074110
2024-05-07
2025-01-18
Loading full text...

Full text loading...

/deliver/fulltext/emiddt/25/3/EMIDDT-25-3-06.html?itemId=/content/journals/emiddt/10.2174/0118715303288678240424074110&mimeType=html&fmt=ahah

References

  1. MarcocciC. CetaniF. Primary hyperparathyroidism.N. Engl. J. Med.2011365252389239710.1056/NEJMcp1106636 22187986
    [Google Scholar]
  2. BilezikianJ.P. BandeiraL. KhanA. CusanoN.E. Hyperparathyroidism.Lancet20183911011616817810.1016/S0140‑6736(17)31430‑7 28923463
    [Google Scholar]
  3. CastellanoE. AttanasioR. BorianoA. PellegrinoM. GarinoF. GianottiL. BorrettaG. Sex difference in the clinical presentation of primary hyperparathyroidism: Influence of menopausal status.J. Clin. Endocrinol. Metab.2017102114148415210.1210/jc.2017‑01080 28938410
    [Google Scholar]
  4. SaponaroF. CetaniF. RepaciA. PagottoU. CiprianiC. PepeJ. MinisolaS. CipriC. VesciniF. ScillitaniA. SalcuniA. PalmieriS. Eller-VainicherC. ChiodiniI. MadeoB. KaraE. CastellanoE. BorrettaG. GianottiL. RomanelliF. CamozziV. FaggianoA. CorbettaS. CianferottiL. BrandiM.L. De FeoM.L. PalermoA. VezzoliG. MainoF. ScaleseM. MarcocciC. Clinical presentation and management of patients with primary hyperparathyroidism in Italy.J. Endocrinol. Invest.201841111339134810.1007/s40618‑018‑0879‑z 29616419
    [Google Scholar]
  5. BilezikianJ.P. KhanA.A. SilverbergS.J. FuleihanG.E.H. MarcocciC. MinisolaS. PerrierN. Sitges-SerraA. ThakkerR.V. GuyattG. MannstadtM. PottsJ.T. ClarkeB.L. BrandiM.L. Evaluation and management of primary hyperparathyroidism: Summary statement and guidelines from the fifth international workshop.J. Bone Miner. Res.202037112293231410.1002/jbmr.4677 36245251
    [Google Scholar]
  6. CoughlanT. DockeryF. Osteoporosis and fracture risk in older people.Clin. Med.201414218719110.7861/clinmedicine.14‑2‑187 24715132
    [Google Scholar]
  7. RossiniM. AdamiS. BertoldoF. DiacintiD. GattiD. GianniniS. GiustiA. MalavoltaN. MinisolaS. OsellaG. PedrazzoniM. SinigagliaL. ViapianaO. IsaiaG.C. Guidelines for the diagnosis, prevention and management of osteoporosis.Reumatismo201668113910.4081/reumatismo.2016.870 27339372
    [Google Scholar]
  8. KanisJ.A. World Health Organization Scientific Group. Assessment of osteoporosis at the primary healthcare level. Technical Report.WHO Collaborating Centre, University of Sheffield, UK.2008Available from: http://www.shef.ac.uk/FRAX/index.htm
    [Google Scholar]
  9. MarcocciC. BrandiM.L. ScillitaniA. CorbettaS. FaggianoA. GianottiL. MigliaccioS. MinisolaS. Italian society of endocrinology consensus statement: Definition, evaluation and management of patients with mild primary hyperparathyroidism.J. Endocrinol. Invest.201538557759310.1007/s40618‑015‑0261‑3 25820553
    [Google Scholar]
  10. CastellanoE. AttanasioR. BorianoA. BorrettaV. TassoneF. BorrettaG. Diabetes and bone involvement in primary hyperparathyroidism: Literature review and our personal experience.Front. Endocrinol.20211266598410.3389/fendo.2021.665984 33953702
    [Google Scholar]
  11. CastellanoE. AttanasioR. BorianoA. BorrettaG. Clinical presentation of primary hyperparathyroidism in older adults.J. Endocr. Soc.20193122305231210.1210/js.2019‑00316 31745527
    [Google Scholar]
  12. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification.Am. J. Kidney Dis.2002392S1S266 11904577
    [Google Scholar]
  13. KanisJ.A. KanisJ.A. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report.Osteoporos. Int.19944636838110.1007/BF01622200 7696835
    [Google Scholar]
  14. RubinM.R. LeeK.H. McMahonD.J. SilverbergS.J. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism.J. Clin. Endocrinol. Metab.20038831174117810.1210/jc.2002‑020667 12629102
    [Google Scholar]
  15. NilssonS. KoehlerK.F. GustafssonJ.Å. Development of subtype-selective oestrogen receptor-based therapeutics.Nat. Rev. Drug Discov.2011101077879210.1038/nrd3551 21921919
    [Google Scholar]
  16. SilverbergS.J. ClarkeB.L. PeacockM. BandeiraF. BoutroyS. CusanoN.E. DempsterD. LewieckiE.M. LiuJ.M. MinisolaS. RejnmarkL. SilvaB.C. WalkerM.D. BilezikianJ.P. Current issues in the presentation of asymptomatic primary hyperparathyroidism: Proceedings of the Fourth International Workshop.J. Clin. Endocrinol. Metab.201499103580359410.1210/jc.2014‑1415 25162667
    [Google Scholar]
  17. SilvaB.C. CusanoN.E. BilezikianJ.P. Primary hyperparathyroidism.Best Pract. Res. Clin. Endocrinol. Metab.202438110124710.1016/j.beem.2018.09.013 30477754
    [Google Scholar]
  18. SeibC.D. MengT. SuhI. CiscoR.M. LinD.T. MorrisA.M. TrickeyA.W. KebebewE. Undertreatment of primary hyperparathyroidism in a privately insured US population: Decreasing utilization of parathyroidectomy despite expanding surgical guidelines.Surgery20211691879310.1016/j.surg.2020.04.066 32654861
    [Google Scholar]
  19. NilssonM. StåhlE. ÅkessonK.E. ThierM. NordenströmE. AlmquistM. BergenfelzA. Reduced fracture incidence in patients having surgery for primary hyperparathyroidism.Clin. Endocrinol.202297327628310.1111/cen.14703 35192220
    [Google Scholar]
  20. SeibC.D. SuhI. MengT. TrickeyA. SmithA.K. FinlaysonE. CovinskyK.E. Kurella TamuraM. KebebewE. Patient factors associated with parathyroidectomy in older adults with primary hyperparathyroidism.JAMA Surg.2021156433434210.1001/jamasurg.2020.6175 33404646
    [Google Scholar]
  21. KhanR. MartinJ. DasG. The impact of observation versus parathyroidectomy on bone mineral density and fracture risk determined by frax tool in patients with primary hyperparathyroidism.J. Clin. Densitom.202124457158010.1016/j.jocd.2020.12.005 33390308
    [Google Scholar]
  22. LundstamK. HeckA. GodangK. MollerupC. BaranowskiM. PernowY. AasT. HessmanO. RosénT. NordenströmJ. JanssonS. HellströmM. BollerslevJ. Effect of surgery versus observation: Skeletal 5-year outcomes in a randomized trial of patients with primary HPT (the SIPH study).J. Bone Miner. Res.20173291907191410.1002/jbmr.3177 28543873
    [Google Scholar]
  23. YehM.W. ZhouH. AdamsA.L. ItuarteP.H.G. LiN. LiuI.L.A. HaighP.I. The relationship of parathyroidectomy and bisphosphonates with fracture risk in primary hyperparathyroidism.Ann. Intern. Med.20161641171572310.7326/M15‑1232 27043778
    [Google Scholar]
  24. Ejlsmark-SvenssonH. RolighedL. HarsløfT. RejnmarkL. Risk of fractures in primary hyperparathyroidism: A systematic review and meta-analysis.Osteoporos. Int.20213261053106010.1007/s00198‑021‑05822‑9 33527175
    [Google Scholar]
  25. SeibC.D. MengT. SuhI. HarrisA.H.S. CovinskyK.E. ShobackD.M. TrickeyA.W. KebebewE. TamuraM.K. Risk of fracture among older adults with primary hyperparathyroidism receiving parathyroidectomy vs nonoperative management.JAMA Intern. Med.20221821101810.1001/jamainternmed.2021.6437 34842909
    [Google Scholar]
  26. RaoD.S. PhillipsE.R. DivineG.W. TalposG.B. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism.J. Clin. Endocrinol. Metab.200489115415542210.1210/jc.2004‑0028 15531491
    [Google Scholar]
  27. AmbroginiE. CetaniF. CianferottiL. VignaliE. BantiC. ViccicaG. OppoA. MiccoliP. BertiP. BilezikianJ.P. PincheraA. MarcocciC. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: A prospective, randomized clinical trial.J. Clin. Endocrinol. Metab.20079283114312110.1210/jc.2007‑0219 17535997
    [Google Scholar]
  28. BollerslevJ. JanssonS. MollerupC.L. NordenströmJ. LundgrenE. TørringO. VarhaugJ.E. BaranowskiM. AanderudS. FrancoC. FreyschussB. IsaksenG.A. UelandT. RosenT. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: A prospective, randomized trial.J. Clin. Endocrinol. Metab.20079251687169210.1210/jc.2006‑1836 17284629
    [Google Scholar]
  29. PretoriusM. LundstamK. HeckA. FagerlandM.W. GodangK. MollerupC. FougnerS.L. PernowY. AasT. HessmanO. RosénT. NordenströmJ. JanssonS. HellströmM. BollerslevJ. Mortality and morbidity in mild primary hyperparathyroidism: Results from a 10-year prospective randomized controlled trial of parathyroidectomy versus observation.Ann. Intern. Med.2022175681281910.7326/M21‑4416 35436153
    [Google Scholar]
  30. El MiedanyY. FRAX: re-adjust or re-think.Arch. Osteoporos.202015115010.1007/s11657‑020‑00827‑z 32989561
    [Google Scholar]
  31. Management of osteoporosis in postmenopausal women: The 2021 position statement of The North American Menopause Society.Menopause202128997399710.1097/GME.0000000000001831 34448749
    [Google Scholar]
  32. KhoslaS. MeltonJ.III Fracture risk in primary hyperparathyroidism.J. Bone Miner. Res.200217Suppl. 2N103N107 12412786
    [Google Scholar]
  33. AsprayT.J. HillT.R. Osteoporosis and the ageing skeleton.Subcell. Biochem.20199145347610.1007/978‑981‑13‑3681‑2_16 30888662
    [Google Scholar]
  34. SeibC.D. Chomsky-HigginsK. GosnellJ.E. ShenW.T. SuhI. DuhQ.Y. FinlaysonE. Patient frailty should be used to individualize treatment decisions in primary hyperparathyroidism.World J. Surg.201842103215322210.1007/s00268‑018‑4629‑3 29696330
    [Google Scholar]
  35. CastellanoE. AttanasioR. BorianoA. BorrettaG. The clinical presentation of primary hyperparathyroidism: A southern european perspective over the last 2 decades.Endocr. Pract.201824121023102910.4158/EP‑2018‑0344 30289298
    [Google Scholar]
  36. RubinM.R. BilezikianJ.P. McMahonD.J. JacobsT. ShaneE. SirisE. UdeskyJ. SilverbergS.J. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years.J. Clin. Endocrinol. Metab.20089393462347010.1210/jc.2007‑1215 18544625
    [Google Scholar]
/content/journals/emiddt/10.2174/0118715303288678240424074110
Loading
/content/journals/emiddt/10.2174/0118715303288678240424074110
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test